论文部分内容阅读
目的:探讨在肝细胞肝癌中乙酰肝素酶(heparanase,HPA)mRNA的表达和临床意义,及其同患者预后和临床病理特征的关系。方法:用实时荧光定量PCR检测30例肝细胞肝癌患者肝癌肝组织及非肝癌肝组织中乙酰肝素酶基因和GAPDH基因的表达,通过2-△△CT方法分析相对基因表达差异。结果:肝癌组织中HPA mRNA的表达水平明显低于同一患者非肝癌肝组织中该基因的表达。结果采用配对样本的Wilcoxon符号秩检验,P=0.027<0.05,差异有显著性。结论:HPA mRNA表达的降低可能是导致肝癌发生和进展的原因。
Objective: To investigate the expression and clinical significance of heparanase (HPA) mRNA in hepatocellular carcinoma and its relationship with prognosis and clinicopathological features. Methods: The expression of heparanase gene and GAPDH gene in hepatocellular carcinoma and non-hepatocellular carcinoma liver tissues of 30 HCC patients were detected by real-time fluorescence quantitative PCR. The relative gene expression differences were analyzed by 2- △△ CT. Results: The expression of HPA mRNA in HCC tissues was significantly lower than that in non-HCC tissues of the same patient. The results using the paired samples Wilcoxon signed rank test, P = 0.027 <0.05, the difference was significant. Conclusion: The decreased expression of HPA mRNA may be responsible for the occurrence and progression of hepatocellular carcinoma.